74 completed, 11 unknown, 7 terminated, 5 not yet recruiting. 52 Phase 1, 30 Phase 2, 14 Phase 3, 4 Phase 4, 2 Not applicable.
Follow Filoviridae Infections: new trials by email Literature Review of Filoviridae Infections trials Research Report on Filoviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Ervebo, Inmazeb - Ebola Virus Disease | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 132 | 2027-01-01 | 2026-01-22 |
| Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC DECIPHER bioassay - Ebola Hemorrhagic Fever | Not yet recruiting | Institute of Tropical Medicine, Belgium | 100 | 2027-01-01 | 2026-07-07 | |
| Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA FORTIFIEDx and DECIPHER bioassays - Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever | Not yet recruiting | Institute of Tropical Medicine, Belgium | 150 | 2027-01-01 | 2026-07-02 | |
| Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo Candidate BDBV vaccine, Active comparator - Ebola Hemorrhagic Fever, Bundibugyo Virus Disease | Phase 2 / Phase 3 | Not yet recruiting | Jean-Pierre Van geertruyden | 3620 | 2026-10-20 | 2026-10-05 |
| BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies ERVEBO Vaccination - Ebola, Bundibugyo Virus Disease (BVD) | Phase 4 | Recruiting | Epicentre | 20000 | 2026-09-19 | 2026-10-29 |
| EBOla Post-Exposure Prophylaxis Ervebo, Inmazeb - Ebola Virus Disease | Phase 3 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 160 | 2026-09-01 | 2026-01-22 |
| Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure ERVEBO® (rVSV∆G-ZEBOV-GP) - Ebola Vaccine | Phase 3 | Withdrawn | Universitätsklinikum Hamburg-Eppendorf | 2026-06-01 | 2026-06-04 | |
| A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health rVSVΔG-SUDV-GP, Placebo - Sudan Virus Disease | Phase 1 | Recruiting | International AIDS Vaccine Initiative | 112 | 2026-05-08 | 2026-09-21 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health rVSV∆G-MARV-GP, Placebo - Marburg Virus Disease | Phase 1 | Active not recruiting | International AIDS Vaccine Initiative | 112 | 2026-03-27 | 2026-10-30 |
| REVIVE (Response to the Ebola Virus Vaccine) rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO) - Ebola Virus Disease | Phase 4 | Active not recruiting | Tulane University | 40 | 2025-12-01 | 2026-06-04 |
| A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults cAd3-Marburg Vaccine, Placebo - Marburg Virus Disease | Phase 2 | Active not recruiting | Albert B. Sabin Vaccine Institute | 200 | 2025-04-14 | 2026-09-10 |
| Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC Zabdeno® booster, Ervebo® booster - Ebola Virus Disease | Phase 3 | Recruiting | Institute of Tropical Medicine, Belgium | 624 | 2025-02-25 | 2025-03-18 |
| Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia Ebola, Post-Acute Ebola Syndrome | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 328 | 2025-02-14 | 2026-10-29 | |
| Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP - Ebola Virus Disease, COVID-19 | Phase 4 | Unknown | University of Birmingham | 72 | 2024-10-01 | 2024-09-19 |
| Immunology of Ebola Vaccine Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water - Ebola Virus Disease | Phase 2 | Active not recruiting | Emory University | 30 | 2024-08-06 | 2026-01-22 |
| Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects PHV01, Placebo - Marburg Virus Disease | Phase 1 | Completed | Public Health Vaccines LLC | 36 | 2024-02-05 | 2025-09-05 |
| Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults cAd3-Marburg vaccine, Placebo - Marburg Virus Disease | Phase 2 | Completed | Albert B. Sabin Vaccine Institute | 126 | 2023-10-19 | 2025-07-23 |
| Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda Ebola+D intervention - Ebola Virus Disease | Not applicable | Unknown | MRC/UVRI and LSHTM Uganda Research Unit | 1000 | 2023-09-22 | 2023-10-23 |
| Community Preparedness for Outbreak Response and Readiness for Ebola Vaccination in Liberia Community Clusters - Ebola Virus Disease | Unknown | UL-PIRE Africa Center | 1500 | 2023-06-01 | 2023-06-05 | |
| Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Ad26.ZEBOV, MVA-BN-Filo - Virus Diseases, Hemorrhagic Fever, Ebola | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 133 | 2022-09-19 | 2025-05-11 |
Showing 20 of 111. Sign in to see all of them.
Hemorrhagic Fever, Ebola (103) · Hemorrhagic Fevers, Viral (18) · Marburg Virus Disease (12) · Virus Diseases (4) · Acquired Immunodeficiency Syndrome (3) · RNA Virus Infections (3) · Communicable Diseases, Emerging (2) · Infections (2) · Mononegavirales Infections (2) · Acquired angioedema (1) · Angioedemas, Hereditary (1) · Bacterial Infections (1) · COVID-19 (1) · Chikungunya Fever (1)
Infections (109) · Mononegavirales Infections (109) · RNA Virus Infections (108) · Virus Diseases (107) · Hemorrhagic Fevers, Viral (93) · Animal Diseases (12) · Monkey Diseases (12) · Primate Diseases (12) · Pathological Conditions, Signs and Symptoms (5) · Communicable Diseases (4) · Pathologic Processes (4) · Blood-Borne Infections (3) · Disease Attributes (3) · Genital Diseases (3)
Saline Solution (5) · Ebola Vaccines (4) · ansuvimab (3) · atoltivimab, maftivimab, and odesivimab-ebgn drug combination (3) · MenACWY (2) · ZMapp (2) · favipiravir (2) · galidesivir (2) · remdesivir (2) · AVI-7288 (1) · Amiodarone (1) · Atorvastatin (1) · Azithromycin (1) · BNT162 Vaccine (1) · COVID-19 Serotherapy (1)
National Institute of Allergy and Infectious Diseases (NIAID) (21) · University of Oxford (8) · Janssen Vaccines & Prevention B.V. (7) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (6) · Institute of Tropical Medicine, Belgium (5) · London School of Hygiene and Tropical Medicine (5) · Sarepta Therapeutics, Inc. (4) · ANRS, Emerging Infectious Diseases (3) · Albert B. Sabin Vaccine Institute (3) · Jiangsu Province Centers for Disease Control and Prevention (3) · Arbutus Biopharma Corporation (2) · BioCryst Pharmaceuticals (2) · Clinical Research Management, Inc. (2) · Epicentre (2) · Institut National de la Santé Et de la Recherche Médicale, France (2)
United States (35) · Democratic Republic of the Congo (11) · Sierra Leone (11) · Uganda (11) · Liberia (10) · Guinea (9) · United Kingdom (7) · Kenya (6) · Russia (6) · China (3) · Germany (3) · Mali (3) · Tanzania (3) · Burkina Faso (2) · Canada (2)
Alison Heald, MD (3) · Deborah Watson-Jones, PhD (3) · Richard T Davey, M.D. (3) · Bailah Leigh, MD (2) · Bridgette J Billioux, M.D. (2) · Julie E Ledgerwood, D.O. (2) · Kawsar Talaat, MD (2) · Konstantin Zhdanov, MD, PhD (2) · Abdoul Habib Beavogui (1) · Adrian V Hill (1) · Ali Ellebedy, PhD (1) · Alie H Wurie (1) · Alimou Camara, Dr. (1) · Angela Huttner, MD (1)
PMID 28647166, PMID 25426834, PMID 25830326, PMID 26546548, PMID 26659569, PMID 28017642, PMID 30407513, PMID 30855742, PMID 34930928, PMID 35182042, PMID 38603720, PMID 11009541, PMID 11395204, PMID 14741143, PMID 1538192, PMID 15577929, PMID 15983268, PMID 16375711, PMID 17548132, PMID 17553602, PMID 17762021, PMID 22342706, PMID 23125444, PMID 23170176, PMID 24738640, PMID 25225676, PMID 25540891, PMID 25558097, PMID 25629663, PMID 25817373, PMID 25955968, PMID 25974635, PMID 26200980, PMID 26725120, PMID 26725450, PMID 26735992, PMID 26768569, PMID 26768570, PMID 26768572, PMID 26930627, PMID 27004234, PMID 27046271, PMID 27382077, PMID 27732819, PMID 27959686, PMID 28231247, PMID 28434944, PMID 28708962, PMID 29627147, PMID 29659889
2019 (2), 2014 (1), 2015 (1), 272201300017C-18-0-1 (1)